Search

Author/Creator Wilding, George

1. A Novel Artificial Intelligence–Powered Method for Prediction of Early Recurrence of Prostate Cancer After Prostatectomy and Cancer Drivers. (22nd February 2022)

Authors:
Huang, Wei; Randhawa, Ramandeep; Jain, Parag; Hubbard, Samuel; Eickhoff, Jens; Kummar, Shivaani; Wilding, George; Basu, Hirak; Roy, Rajat
Journal:
JCO Clinical Cancer Informatics
Issue:
Volume 6(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α, 24(S)Dihydroxyvitamin D2) in patients with advanced cancer. (December 2015)

Authors:
Wisinski, Kari B; Ledesma, Wendy M; Kolesar, Jill; Wilding, George; Liu, Glenn; Douglas, Jeffrey; Traynor, Anne M; Albertini, Mark; Mulkerin, Daniel; Bailey, Howard H
Journal:
Journal of oncology pharmacy practice
Issue:
Volume 21:Number 6(2015)
Page Start:
416
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Issue 10032 (14th May 2016)

Authors:
Haas, Naomi B; Manola, Judith; Uzzo, Robert G; Flaherty, Keith T; Wood, Christopher G; Kane, Christopher; Jewett, Michael; Dutcher, Janice P; Atkins, Michael B; Pins, Michael; Wilding, George; Cella, David; Wagner, Lynne; Matin, Surena; Kuzel, Timothy M; Sexton, Wade J; Wong, Yu-Ning; Choueiri, T...
Journal:
Lancet
Issue:
Volume 387:Issue 10032(2016)
Page Start:
2008
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Assessment of adherence and relative dose intensity with oral chemotherapy in oncology clinical trials at an academic medical center. (July 2018)

Authors:
Engle, Jeff A; Traynor, Anne M; Campbell, Toby C; Wisinski, Kari B; LoConte, Noelle; Liu, Glenn; Wilding, George; Kolesar, Jill M
Journal:
Journal of oncology pharmacy practice
Issue:
Volume 24:Number 5(2018)
Page Start:
348
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis. (28th March 2013)

Authors:
Rini, Brian I.; Garrett, May; Poland, Bill; Dutcher, Janice P.; Rixe, Olivier; Wilding, George; Stadler, Walter M.; Pithavala, Yazdi K.; Kim, Sinil; Tarazi, Jamal; Motzer, Robert J.
Journal:
Journal of clinical pharmacology
Issue:
Volume 53:Number 5(2013:May)
Page Start:
491
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Phase II open label, multi‐center clinical trial of modulation of intermediate endpoint biomarkers by 1α‐hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin. Issue 9 (17th January 2013)

Authors:
Gee, Jason; Bailey, Howard; Kim, KyungMann; Kolesar, Jill; Havighurst, Tom; Tutsch, Kendra D.; See, William; Cohen, Michael B.; Street, Nick; LeVan, Leon; Jarrard, David; Wilding, George
Journal:
Prostate
Issue:
Volume 73:Issue 9(2013)
Page Start:
970
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Prostate cancer cells survive anti‐androgen and mitochondrial metabolic inhibitors by modulating glycolysis and mitochondrial metabolic activities. Issue 12 (25th June 2021)

Authors:
Basu, Hirak S.; Wilganowski, Nathaniel; Robertson, Samantha; Reuben, James M.; Cohen, Evan N.; Zurita, Amado; Ramachandran, Sumankalai; Xiao, Lian‐Chun; Titus, Mark; Wilding, George
Journal:
Prostate
Issue:
Volume 81:Issue 12(2021)
Page Start:
799
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗